News

Zacks.com on MSN7d
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.
Nasdaq9d
New Analyst Forecast: $KALV Given $27.0 Price Target - Nasdaq
We just received data on a new analyst forecast for $KALV. Andrew Fein from HC Wainwright & Co. set a price target of 27.0 for KALV.
KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
Detailed price information for Kalvista Pharmaceuticals Inc (KALV-Q) from The Globe and Mail including charting and trades.
Nasdaq7d
KALV Stock Moves More Than 30% in a Week: What Is Driving This ... - Nasdaq
Shares of KalVista Pharmaceuticals KALV have soared 36% in the past week, all thanks to the FDA’s approval of its lead pipeline drug for the hereditary angioedema (HAE) indication. Earlier this ...
KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.
KalVista Pharmaceuticals Gains FDA Approval for EKTERLY®
Detailed price information for Kalvista Pharmaceuticals Inc (KALV-Q) from The Globe and Mail including charting and trades.
Business Wire10d
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Morningstar2d
KALV - KalVista Pharmaceuticals Inc Key Metrics | Morningstar
Review the current KalVista Pharmaceuticals Inc (KALV:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if KALV is the best investment for you.